Wall Street is officially spooked. September started with warning signs flashing across every major index, pushing investors straight into foreign banks and gold miners. This is about survival. August ended with the S&P 500 breaching 6,500, and the Dow Jones notching fresh highs. But that meant nothing to those who’ve been here before. Historically, this […]Wall Street is officially spooked. September started with warning signs flashing across every major index, pushing investors straight into foreign banks and gold miners. This is about survival. August ended with the S&P 500 breaching 6,500, and the Dow Jones notching fresh highs. But that meant nothing to those who’ve been here before. Historically, this […]

Wall Street investors are fleeing U.S. stocks in September and moving into foreign banks and gold miners

Wall Street is officially spooked. September started with warning signs flashing across every major index, pushing investors straight into foreign banks and gold miners. This is about survival.

August ended with the S&P 500 breaching 6,500, and the Dow Jones notching fresh highs. But that meant nothing to those who’ve been here before. Historically, this month tanks the markets, and nobody’s betting against that now.

Data from Dow Jones shows that the Dow, S&P, and Nasdaq usually take their worst hit in September. So investors are bailing on U.S. stocks and heading overseas.

According to CNBC, money managers are diving deep into international equities in 2025. Demand’s climbing fast. One of the biggest moves came from Lazard Asset Management, whose global portfolios are loading up on European and Asian banks, gold miners, and chipmakers.

They’re backing away from the U.S. market, blaming stretched valuations, dollar weakness, and geopolitical messes, and building new positions through the Lazard International Dynamic Equity ETF, a $422 million fund that launched in May after converting from a mutual fund. It carries a 0.40% expense ratio and currently holds a five-star Morningstar rating.

Lazard bets on foreign banks and miners as U.S. tech gets dumped

Paul Moghtader, managing director at Lazard and the head of the firm’s Advantage Team, told CNBC that volatility in 2025 has gotten worse, not better.

“Markets are increasingly volatile and risky. We’re seeing risk injected from many different sources, and an international exposure is getting more attractive relative to U.S. for many reasons, including the valuation, more shareholder focus,” Paul said.

He said he breaks every stock down using four categories: valuation, growth, quality, and sentiment. They even factor in how a company’s beta relates to GDP growth, a macroeconomic layer that Paul said lets them weigh the risk or opportunity of every position inside a real-world backdrop.

The Lazard ETF, trading under the ticker IEQ, now includes stocks like Taiwan Semiconductor Manufacturing, BNP Paribas, Novartis, Tencent Holdings, and Samsung Electronics. Canadian gold miners are also in, thanks to strong signals from Lazard’s in-house screening models.

The firm’s overweight on European banks, particularly BNP, which is the second-largest holding after Taiwan Semi. BNP now holds just over 2% of the entire fund. Paul pointed to BNP’s AXA Investment Managers acquisition, finalized on June 30, which made BNP the fifth-biggest asset manager in Europe.

Other top bank names in IEQ include Societe Generale, Barclays, Japan Post Bank, and State Bank of India. Societe Generale is up a massive 94% this year, helped by strong Q2 earnings and a rebound in retail operations.

Barclays is up 34%, and Japan Post Bank has gained 25%. Lazard’s strategy favors these names for their low valuations and above-average dividend yields, a sharp contrast to overvalued U.S. tech.

The ETF also includes a smaller position in Canadian gold miners. Around 1% of the portfolio is in Barrick Mining, Kinross Gold, and Torex Gold. Barrick is up 72% this year, and Kinross has exploded by 125%.

Paul said the team sees gold as protection against macro uncertainty, especially in a year like this, where both rates and currencies are unpredictable. The portfolio has been moving away from software entirely.

Lazard dumped names like AppLovin, Gartner, and Cadence Design Systems in August, citing the rise of AI. Paul said software development is becoming easier and cheaper with AI tools, making some companies less attractive from a value and growth standpoint.

In response, the firm has picked up shares in Amphenol, Erickson, Western Digital, and NetGear, betting instead on hardware and connectivity players.

Outside of Lazard’s moves, broader sector shifts are showing similar cracks. Europe’s banking sector hit its highest level since 2008 at the beginning of August. Names like Commerzbank are up over 100% year-to-date, thanks to strong earnings and renewed deal activity.

Meanwhile, media stocks are falling apart. They’ve dropped more than 8% over the last two months. AI concerns are tearing into European names, especially in advertising. WPP posted a 71% fall in pre-tax profit in the first half of the year and slashed its full-year outlook, making it the worst performer in the entire sector.ft.

Get seen where it counts. Advertise in Cryptopolitan Research and reach crypto’s sharpest investors and builders.

Market Opportunity
Index Cooperative Logo
Index Cooperative Price(INDEX)
$0.5335
$0.5335$0.5335
+5.18%
USD
Index Cooperative (INDEX) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26